Anzeige
Mehr »
Login
Freitag, 10.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
GameStop 2.0? ...alle Anzeichen für den nächsten großen Short Squeeze!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ESKZ | ISIN: CA9839891046 | Ticker-Symbol:
Branche
IT-Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
XCYTE DIGITAL CORP Chart 1 Jahr
5-Tage-Chart
XCYTE DIGITAL CORP 5-Tage-Chart
ACCESSWIRE
213 Leser
Artikel bewerten:
(1)

Xcyte Digital Corp. Announces New CFO

Finanznachrichten News

POMPANO BEACH, FL / ACCESSWIRE / January 9, 2025 / Xcyte Digital Corp. (TSXV:XCYT) ("Xcyte", or the "Company"), a trusted global events technology company, specializing in next-generation event solutions, announced today that its Chief Financial Officer, Nelson Lamb, will be departing the Company after successfully helping complete Xcyte's Qualifying Transaction (as such term is defined in Policy 2.4-Capital Pool Companies of the TSX Venture Exchange (the "TSXV")) and positioning the Company for it's next phase of growth.

Xcyte also announced the appointment of Michael Ertle as the new Chief Financial Officer, as part of a comprehensive agreement to provide full accounting and administrative services with a team of professionals with Brio Financial Group ("Brio") effective immediately. Brio's compensation will consist of a monthly retainer and a stock option grant. Brio has been granted today, an aggregate of 400,000 stock options (the "Options"), each of which will be exercisable into one share at a price of C$0.30 per share until the earlier of (i) three years from the date of grant, (ii) 90 days after Brio ceases to provide services to the Company or any of its subsidiaries in any capacity.

Michael Ertle replaces Nelson Lamb who served as CFO since July, 2023. Mr. Ertle brings over 12 years of international corporate accounting and financial management experience. With a proven track record in budgeting, forecasting, and financial modeling, he has consistently driven operational efficiency and growth. His expertise spans financial reporting, regulatory compliance, and strategic planning.

Most recently, Mr. Ertle served as a Manager and Consultant at Brio Financial Services in New York, where he prepared detailed financial statements, led audit processes, collaborated on M&A due diligence, and optimized resource allocation strategies. Prior to this, he held the role of Portfolio Controller at a private equity firm. Mr. Ertle holds a Juris Doctor from Cleveland State University and a Bachelor's Degree in Accounting from Marquette University. Brio Financial Group is a forward-thinking, full-service financial consulting firm that brings experienced finance and accounting expertise to both public and private companies. Founded in 2010, Brio has consulted to over 125 companies as well as numerous banks, hedge funds, venture capital funds and private equity firms.

"I would like to thank Nelson for his hard work and contributions during his tenure and wish him all the best in his future endeavours," said Randy Selman, CEO of Xcyte Digital. "I would also like to welcome Michael as our new CFO. As Xcyte embarks on its next chapter of growth, we remain dedicated to providing outstanding technology and service to our clients across the globe. Michael's leadership and financial expertise will be instrumental as we continue to advance our strategic objectives and drive shareholder value."

About Xcyte Digital

Xcyte Digital (TSXV:XCYT) is a trusted global events technology company, specializing in next-generation applications for physical, hybrid, virtual, immersive, and phone-based events. Combining proprietary technology with a robust partner ecosystem, Xcyte offers both do-it-yourself and managed services, ensuring secure and scalable solutions worldwide. Thousands of clients, from innovative startups to major corporations, rely on Xcyte's cost-effective solutions to meet their event needs. Xcyte Digital is headquartered in Canada and the USA, with operations across the globe. Visit us at xcytedigital.com.

About Brio Financial Group

Brio Financial Group is a forward-thinking, full-service financial consulting firm that brings experienced finance and accounting expertise to both public and private companies. Founded in 2010. Brio has consulted to over 125 companies as well as numerous banks, hedge funds, venture capital funds and private equity firms. Brio has earned a reputation for exceptional client service as a leading outsourced CFO and financial reporting firm. The Brio management team consists of seasoned executives supported by a professional team with experience in finance, complex accounting and reporting, valuation, modeling and taxation.

For further information, please contact:

Xcyte Digital Corp.
Randy Selman, Chief Executive Officer and Director
Phone: (647) 777 7501
Email: investment@xcytedigital.com

Investor Relations
Nikhil Thadani, Sophic Capital
Email: nik@sophiccapital.com
Phone: (647) 777 7501

To receive Xcyte investor news, please sign up at https://xcytedigital.com/investors/

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Xcyte Digital



View the original press release on accesswire.com

© 2025 ACCESSWIRE
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.